Ubs Group Ag Ideaya Biosciences, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,056,577 shares of IDYA stock, worth $34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,056,577

Previous 751,905 40.52%

Holding current value

$34 Million

Previous $15.8 Million 81.9%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$21.12 - $27.21 $6.43 Million - $8.29 Million	304,672 Added 40.52%	1,056,577 $28.7 Million
Q2 2025 Aug 14, 2025	BUY	$14.5 - $22.63 $4.38 Million - $6.83 Million	301,758 Added 67.04%	751,905 $15.8 Million
Q1 2025 May 13, 2025	BUY	$16.38 - $26.0 $518,623 - $823,212	31,662 Added 7.57%	450,147 $7.37 Million
Q4 2024 Feb 14, 2025	BUY	$24.79 - $31.98 $6.91 Million - $8.92 Million	278,938 Added 199.89%	418,485 $10.8 Million
Q3 2024 Nov 14, 2024	SELL	$30.37 - $43.05 $2.71 Million - $3.84 Million	-89,258 Reduced 39.01%	139,547 $4.42 Million

Q2 2024 Aug 13, 2024	SELL	$34.37 - $43.46 $489,566 - $619,044	-14,244 Reduced 5.86%	228,805 $8.03 Million
Q1 2024 May 13, 2024	BUY	$34.2 - $47.13 $3.16 Million - $4.35 Million	92,347 Added 61.28%	243,049 $10.7 Million
Q4 2023 Feb 09, 2024	BUY	$24.59 - $35.83 $2.32 Million - $3.37 Million	94,167 Added 166.56%	150,702 $5.36 Million
Q3 2023 Nov 09, 2023	BUY	$21.07 - $29.77 $1 Million - $1.41 Million	47,486 Added 524.77%	56,535 $1.53 Million
Q2 2023 Aug 11, 2023	SELL	$13.33 - $25.53 $631,908 - $1.21 Million	-47,405 Reduced 83.97%	9,049 $212,000
Q1 2023 May 12, 2023	SELL	$13.49 - $18.72 $784,430 - $1.09 Million	-58,149 Reduced 50.74%	56,454 $775,000
Q4 2022 Feb 08, 2023	BUY	$14.47 - $18.17 $1.44 Million - $1.81 Million	99,753 Added 671.74%	114,603 $2.08 Million
Q3 2022 Nov 10, 2022	BUY	$9.24 - $15.79 $94,654 - $161,752	10,244 Added 222.41%	14,850 $222,000
Q2 2022 Aug 10, 2022	SELL	$8.28 - $13.88 $594,214 - $996,098	-71,765 Reduced 93.97%	4,606 $64,000
Q1 2022 May 16, 2022	SELL	$11.18 - $24.02 $458,335 - $984,723	-40,996 Reduced 34.93%	76,371 $854,000
Q4 2021 Feb 14, 2022	BUY	$20.95 - $26.88 $1.53 Million - $1.96 Million	72,996 Added 164.51%	117,367 $2.77 Million
Q3 2021 Nov 15, 2021	BUY	$17.26 - $27.08 $365,221 - $573,012	21,160 Added 91.16%	44,371 $1.13 Million
Q2 2021 Aug 13, 2021	BUY	$17.76 - $24.83 $192,624 - $269,306	10,846 Added 87.72%	23,211 $487,000
Q1 2021 May 12, 2021	BUY	$13.48 - $23.77 $155,100 - $273,497	11,506 Added 1339.46%	12,365 $291,000
Q4 2020 Feb 11, 2021	BUY	$12.17 - $17.52 $7,314 - $10,529	601 Added 232.95%	859 $12,000
Q3 2020 Nov 12, 2020	SELL	$11.22 - $14.46 $39,909 - $51,434	-3,557 Reduced 93.24%	258 $3,000
Q2 2020 Jul 31, 2020	BUY	$3.59 - $18.57 $11,175 - $57,808	3,113 Added 443.45%	3,815 $54,000
Q1 2020 May 01, 2020	BUY	$3.03 - $10.58 $2,127 - $7,427	702 New	702 $3,000
Q4 2019 Feb 14, 2020	SELL	$5.34 - $9.09 $16,142 - $27,479	-3,023 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.06 - $10.91 $18,319 - $32,980	3,023 New	3,023 $27,000

Others Institutions Holding IDYA

# of Institutions

238

Shares Held

82.1M

Call Options Held

509K

Put Options Held

103K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.54B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account